

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims**

1. (Previously presented): A method of modifying beta-amyloid-induced vasoactivity in individuals with Alzheimer's Disease or other vascular-related diseases or disorders, in which said vascular-related diseases or disorders are selected from the group consisting of cerebral amyloid angiopathy, vascular amyloidosis, hypertension and vasospasm associated with severe post-traumatic head injury, comprising antagonizing the secretory phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 pro-inflammatory pathway by administering a pharmaceutically effective amount of a secretory phospholipase A2 inhibitor to the individual in an amount ranging from between 0.1 ng to 10 mg/kg body weight/day.

2. (Cancelled).

3. (Previously Presented): The method according to claim 1, further defined as down-regulating a soluble A $\beta$  pro-inflammatory pathway.

4-21. (Canceled)

22. (Currently Amended) The method of claim 1, wherein the secretory phospholipase A2 inhibitor is ~~selected from the group consisting of~~ oleyloxyethylphosphocholine, ~~methyl arachidonyl fluorophosphate and arachidonyl~~ trifluoromethyl ketone (AACOCF<sub>3</sub>).

23. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is cerebral amyloid angiopathy.

24. (Previously Presented) The method of claim 1, wherein the vascular-related

disease or disorder is vascular amyloidosis.

25. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is hypertension.

26. (Previously Presented) The method of claim 1, wherein the vascular-related disease or disorder is vasospasm associated with severe post-traumatic head injury.

27. (Currently Amended) The method of claim 1, wherein the secretory phospholipase A2 inhibitor is administered orally, subcutaneously, parenterally, intraperitoneally, intranasally or by implant.

28. (Currently Amended) The method of claim 1, wherein the secretory phospholipase A2 inhibitor is administered orally.

29. (Currently Amended) The method of claim 28, wherein the secretory phospholipase A2 inhibitor is administered in a pharmacological formulation in the form of a tablet, suspension, solution, emulsion, capsule, powder, or syrup.

30. (Previously Presented) A method of treating cerebral amyloid angiopathy, vascular amyloidosis, hypertension or vasospasm associated with severe post-traumatic head injury in an individual, the method comprising administering a pharmaceutically effective amount of a secretory phospholipase A2 inhibitor to the individual.